StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$15.33−0.17 (-1.10%)

Close on Nov 13, 2026Market cap $1.36BP/E –Yield –

Mineralys Therapeutics statistics

59 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Mar 11, 2027 (estimated, after the close)
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$1.36B
$272.32M
Enterprise Value
$1.25B
$146.23M
PB Ratio
2.69
2.00
P/TBV Ratio
2.69
2.22

Share statisticsIndustry

Shares Change (YoY)
41.2%
10.8%
Shares Change (QoQ)
0.20%
0.50%
Float
67M
49M
Shares Held by Insiders
24.1%
11.7%
Shares Held by Institutions
113.7%
56.4%

Short sellingIndustry

Short Interest
8M
–
Short Interest Change
3.35%
-0.80%
Short % of Float
11.5%
9.01%
Short % of Shares Outstanding
8.70%
6.30%
Days to Cover
4.95
5.15

Stock price statisticsIndustry

52-Week High
$47.00
–
52-Week Low
$14.78
–
20-Day Moving Average
$18.28
–
50-Day Moving Average
$22.66
–
200-Day Moving Average
$26.16
–
Average True Range (14)
$1.40
–
Price Change (1 Week)
0.00%
-1.15%
Price Change (1 Month)
-29.2%
-4.87%
Price Change (3 Months)
-41.2%
-21.0%
Price Change (6 Months)
-44.0%
-20.6%
Price Change (YTD)
-57.8%
-23.6%
Price Change (1 Year)
-67.6%
-22.4%
Price Change (3 Years)
114.4%
-29.5%
Average Volume (10 Days)
2M
–
Average Volume (20 Days)
2M
–
Average Volume (90 Days)
1M
–
Relative Volume
1.02
0.70
Relative Strength Index (14)
32.0
43.4
Volatility (1 Year)
61.8%
80.1%
Beta (5 Years)
1.63
1.07

Returns on capitalIndustry

Return on Equity (ROE)
-68.5%
-49.9%
Return on Assets (ROA)
-60.2%
-40.6%
Return on Invested Capital (ROIC)
-80.9%
-32.9%
Return on Capital Employed (ROCE)
-67.5%
-37.9%

Financial positionIndustry

Current Ratio
11.83
3.30
Quick Ratio
1.91
2.39

EfficiencyIndustry

Profits Per Employee
-$4.87M
-$689.41K
Employee Count
76
74
WACC
13.2%
10.2%

Income statement (TTM)Industry

Operating Income
-$389.75M
-$21.37M
Net Income
-$369.97M
-$22.35M
EBITDA
-$389.72M
-$17.21M
EPS (Diluted)
-$4.36
-$0.76

Balance sheetIndustry

Net Cash (Debt)
$101.27M
$17.76M
Net Cash Per Share
$1.15
$0.80
Equity (Book Value)
$503.78M
$53.89M
Book Value Per Share
$5.70
$1.50
Tangible Book Value
$503.78M
$27.13M
Working Capital
$574.92M
$79.99M

Cash flow (TTM)Industry

Operating Cash Flow
-$153.01M
-$12.38M

Dividends and yieldsIndustry

Earnings Yield
-27.3%
-21.8%

Scores and fair valueIndustry

Altman Z-Score
3.72
0.23
Piotroski F-Score
4
4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodMLYSS&P 500DifferenceMLYS per yearS&P 500 per year
1 month-27.0%-3.0%−24.0 pts
3 months-41.2%-2.8%−38.5 pts
Year to date-57.8%+11.5%−69.2 pts
1 year-65.4%+13.5%−78.8 pts
3 years+141.0%+77.7%+63.3 pts+34.1%+21.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

8M MLYS shares were sold short on Oct 30, 2026, up 3.3% from the previous report, or 11.46% of the shares available to trade. At recent volumes it would take 5.0 days to buy them back. Over the last 20 sessions, 24.3% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20267,687,327+3.3%1,551,9965.0
Oct 15, 20267,438,452-4.7%1,396,1595.3
Sep 30, 20267,805,612-15.0%1,513,8255.2
Sep 15, 20269,181,891-1.6%1,443,8146.4
Aug 31, 20269,332,307-3.3%818,57411.4
Aug 14, 20269,645,951+3.6%744,75512.9
Jul 31, 20269,313,645-2.5%618,17815.1
Jul 15, 20269,552,513-13.9%976,4989.8
Jun 30, 202611,098,105+27.6%2,116,0235.2
Jun 15, 20268,698,119-8.2%2,484,2243.5
May 29, 20269,477,459+5.0%1,389,8856.8
May 15, 20269,024,879+5.8%1,102,0438.2

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?